바이오테크 보도자료
-
- Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically dev...
- 2023년 06월 29일
-
- AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
- AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expa...
- 2023년 06월 29일
-
- Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
- Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report. The report highlights the company’s progress on it...
- 2023년 06월 28일
-
- FEELM Captures Seven Prestigious Awards at Vapouround Mena Vape Awards 2023 in Dubai
- FEELM - part of leading atomization technology company SMOORE - has earned high praise at a major industry event in the Middle East. The brand was crowned ‘Best Manufacturer’ and ‘Industry Leader’ at the ann...
- 2023년 06월 28일
-
- World’s Highest Puffs Charge Free Battery Technology “TOPOWER” — Real Disposables Exhibited in Dubai
- FEELM, part of leading atomization technology company SMOORE, showcased its new TOPOWER disposable vape battery solution during a major industry event in the Middle East. The pioneering power technology is i...
- 2023년 06월 26일
-
- Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombin...
- 2023년 06월 26일
-
- ODDITY Announces Filing of Registration Statement for Proposed Initial Public Offering
- ODDITY Tech Ltd. (“ODDITY”), a consumer tech platform that is built to transform the global beauty and wellness market, today announces that it has filed a registration statement on Form F-1 with the U.S. Se...
- 2023년 06월 25일
-
- Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with chroni...
- 2023년 06월 25일
-
- IPS Strengthens Asia and Pacific Presence with New Managing Director, Matthew Shippey
- IPS, a leading provider of architecture, engineering, procurement, construction management, and validation services, announces the appointment of an industry-leading professional, Matthew Shippey, to support...
- 2023년 06월 25일
-
- At the double: leading vape technology brand FEELM shows off two latest advancements in Dubai
- FEELM - part of leading atomization technology company SMOORE - exhibited two game-changing innovations, which have been developed to ‘raise product performance’ across the disposable vape category, during a...
- 2023년 06월 23일
-
- Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
- Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medi...
- 2023년 06월 22일
-
- No Charge, 6000 Puffs: ‘Power Alpha’ Breaks the Glass Ceiling of Disposable Solution
- SMOORE, a global leader in atomization technology, displayed its groundbreaking disposable solution, ‘Power Alpha’, at the World Vape Show 2023 in Dubai (June 21st - 23rd). Just a few months ago, Power Alpha...
- 2023년 06월 22일
-
- Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)
- The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122 in amyotrophic lateral sclerosis (ALS). Th...
- 2023년 06월 22일
전시회
